Smarter Drug Development for Biologics with In Silico Modelling

Computational approaches to biologics developability, formulation optimisation and stability prediction, with case studies on risk reduction.

July 1st 2025

16:00pm (CET) / 10:00am (ET)

View Linkedin Event

OVERVIEW

The development of new protein therapeutics is a complex and costly process, often hindered by late-stage failures due to poor drug-like properties or instability of drug candidates. In silico modeling has emerged as a powerful tool to identify potential risks early, analyze structural properties, and inform formulation optimization strategies. The integration of computational approaches with experimental developability assessments enables data-driven decision-making, reducing development time, costs and material constraints. This webinar explores recent advances in in-silico tools and demonstrates how computational methods streamline drug development and enhance formulation success.

Dr. Tim Menzen, Chief Technology Officer and Dr. Andrea Arsiccio, Senior Scientist both of Coriolis Pharma, will lead this informative session exploring computational approaches in pharmaceutical development. They will cover in silico applications and their key areas of use including particle identification, lyophilization process development, and developability assessment, alongside the integration of in silico models with experimental approaches to optimise drug development.

Including case studies demonstrating in silico modeling’s role in developability assessment and early formulation development, highlighting how these approaches minimise risks, shorten development times, and enhance decision-making. Gain valuable insights on how computational modeling is revolutionising pharmaceutical development workflows and creating more efficient pathways from discovery to clinical application, benefiting scientists and researchers across the industry.

An interactive Q&A session with the speakers will conclude the webinar.

Addressed Challenges

01Identifying potential stability, solubility, or manufacturability issues early enough to prevent costly late-stage development failures.

02Reducing time-consuming and expensive experimental work by using computational predictions to guide and prioritise laboratory testing.

03Minimising dependency on physical material during early-stage assessments where supply is limited and waste must be controlled.

04Avoiding poor decisions in formulation development by using in silico tools to guide excipient selection and processing conditions.

WHAT YOU WILL LEARN

01Understand how computational approaches contribute to drug developability assessments and formulation optimisation for biologics programmes.

02Discover how in silico predictions can reduce costs, shorten development timelines, and mitigate risks in preclinical drug product development.

03Review real-world case studies where in silico modelling successfully guided formulation strategies and overcame development challenges.

04Learn how computational modelling integrates with experimental approaches to optimise lyophilisation, particle analysis, and developability decisions.

Reserve Your Seat

First Name

Last Name

Business Email

Job Title

Company

Telephone

Country

Pharma Consent

I accept the Privacy Policy and consent to receiving updates from Pharma D-mand.

Partner Consent

I agree to share my details with Coriolis Pharma for educational follow-up.

SPEAKERS

Dr. Tim Menzen

Chief Technology Officer (CTO)

Dr. Tim Menzen is Coriolis’ Chief Technology Officer (CTO). He is a trained pharmacist who received his PhD from Ludwig Maximilian University (LMU) in Munich, Germany. Tim joined Coriolis in 2014 and is responsible for internal research projects and scientific relations, including collaborations with partners from industry and academia. He has co-authored over 35 publications in peer-reviewed journals.

Dr. Andrea Arsiccio

Senior Scientist

Andrea Arsiccio is a Senior Scientist at Coriolis Pharma, where he works on projects dealing with the implementation of innovative modelling concepts. He received a master’s degree in chemical engineering from Politecnico di Torino in 2016 followed by a PhD degree in 2020. During his PhD he investigated the computational modelling of proteins, with a special focus on the formulation of biopharmaceuticals. He subsequently worked as a Postdoctoral scholar at the University of California in Santa Barbara and at Politecnico di Torino, and during this time his research focused on molecular dynamics simulations and bioinformatics. His main interests and expertise are in the fields of freeze drying, protein folding and aggregation, and molecular dynamics simulations.

Explore Our Services

Turn Registrants Into Relationships

Most registrants disappear after the session ends. We help you
open the right doors before, during, and after the webinar.

<span>By ticking this box, you agree to the privacy policies of <a href=”https://www.coriolis-pharma.com/data-privacy/” style=”color:white; text-decoration: underline;” target=”_blank”>Coriolis Pharma</a> and <a href=”/wp-content/uploads/2023/08/Livestorm-privacy-policy-en.pdf” style=”color:white; text-decoration: underline;” target=”_blank”>Livestorm</a>, consenting to receiving communications related to this topic and other products or services within their portfolio</span>